top of page
NICE consultation on Review Guide to the Methods of Technology Appraisals Addendum
Cancer52 has commented on a number of aspects of the Methods of Technology Appraisals consultation, and submitted its response to NICE....
Cancer52 response to the NICE consultation
Please find here Cancer52's response to the NICE Methods of Technology Appraisal Consultation, which was submitted to NICE on Tuesday...
New report from Cancer52: percentage of cancer deaths outside the big four rises to 54%
A new report published today (Tuesday 10th June 2014) by Cancer52 shows that the percentage of cancer deaths from those cancers outside...
Briefing paper on Access to Orphan Medicines in the UK
On 5th June 2014, Cancer52 published its Briefing Paper on Access to Orphan Medicines in the UK.
Clara Mackay appointed as interim chair of Cancer52
Cancer52 is delighted to announce that Clara Mackay, Deputy CEO of Pancreatic Cancer UK, has been appointed as interim chair of Cancer52....
NICE consultation on Technology Appraisals Process Guide
On the basis of the increasing experience of our members with NICE Technology Appraisals Cancer52 has commented in detail on a number of...
Cancer52 responds to NICE consultation on Technology Appraisals Process Guide
On the basis of the increasing experience of our members with NICE Technology Appraisals Cancer52 has commented in detail on a number of...
Briefing paper on the UK Strategy for Rare Diseases: Making sure that rare cancers aren’t written ou
On 24th February 2014, Cancer52 published its Briefing Paper on the UK Strategy for Rare Diseases.
Cancer52 publishes briefing paper on the UK Strategy for Rare Diseases
Making sure that rare cancers aren’t written out of the script Cancer52 published its briefing paper on the UK Strategy for Rare...
Briefing paper on NICE and Value Based Assessment (VBA)
On 21st February 2014, Cancer52 published its Briefing Paper "VBA: NICE do it their way".
bottom of page